Consolidation with Loncastuximab Tesirine for Large B-cell Lymphoma Patients in Partial Response after CART: Planned Interim Futility Analysis of a Phase II Trial

Key Points

• Demonstrates therapeutic potential with loncastuximab tesirine in patients showing partial response.
• Key evidence indicates efficacy and safety in a phase II trial for large-B-cell lymphoma within the target population.
• Trial protocol includes planned interim futility analysis to assess treatment outcomes in patients after CART therapy.
• Significance highlights potential advancements in treatment options for large-B-cell lymphoma patients.